Information and interesting ideas

Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.

Tuesday, January 31, 2023

American Society for Mass Spectrometry Course is Offering 15 Short Courses of Interest to Bioanalysts and Biomarker Scientists

ASMS will be offering the Two-Day Short Courses, Saturday and Sunday, June 3 and 4, 2023

 

All of the following two-day short courses will be in-person only at the George R. Brown (GRB) Convention Center in Houston, TX.  Several short courses will now be offered ONLINE, asynchronous to the annual conference.

 

Course offerings:

01 Bioinformatics for Protein Identification

 

02 Clinical Biomarkers: Development and Validation

03 DMPK: Experimentation and Data Interpretation

04 Glycans and Glycoproteins in Mass Spectrometry

05 LC-MS: Practical Maintenance and Troubleshooting

06 LC-MS/MS: Practical Method Development (Saturday one-day course)
            AND Bioanalytical Method Validation (Sunday one-day course)

07 LC-MS/MS: Understanding, Optimizing and Applying Techniques using Electrospray, APCI and APPI                 to Develop Successful Methods for Qualitative and Quantitative Analysis

08 Machine Learning for Mass Spectrometry Data Analysis

09 Native Mass Spectrometry

10 Peptides and Proteins in Mass Spectrometry

 

11 Protein Therapeutics: Practical Characterization and Quantitation by Mass Spectrometry

12 Quantitative Mass Spectrometry

 

13 Quantitative Proteomics: Case Studies

 

14 R for Mass Spectrometry Data Analysis: Getting Started

15 Top-Down Proteomics (Saturday one-day course) 

        AND Top-Down MS Data Analysis and Visualization (Sunday one-day course)

No comments:

Post a Comment

FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made

This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...